Neuropathic pain is a chronic condition wherein pathological pain continues even after the cause of the pain is eliminated. Over the past few decades, scientists and researchers have been increasingly focusing on the discovery of novel therapeutics that are essential to interrupt the signaling cascades required to manage various forms of neuropathic pain. Research and development are expected to play a major role in the overall development of the neuropathic pain therapeutics market during the forecast period. Neuropathic pain is a chronic disease that affects nearly 8% of the global population and continues to remain a major socioeconomic and medical issue.
Some of the most common pharmacological treatments to address neuropathic pain that are widely deployed include tricyclic antidepressants (amitriptyline), repurposed antiepileptic (gabapentin, pregabalin), opioids, and steroids. However, these medications bring along a range of side effects due to which, added pressure is being applied to participants operating in the neuropathic pain therapeutics market to discover new treatment types and approaches. Consistent research and development are being carried out to investigate cellular and molecular mechanisms underlying the switch from nociceptive responses to noxious stimuli to neuropathic pain.
Several players in the market are focusing on attaining approval from the FDA and expanding their product portfolio to gain an advantage in the current market landscape. At the back of these factors, along with growing collaborations between researchers and drug developers, the global neuropathic pain therapeutics market is expected to reach a market value of ~US$ 10.2 Bn by the end of 2030.
Due to the exponential rise in the number of individuals suffering from neuropathic pain, research and development activities have accelerated at a rapid pace. Market participants are increasingly focusing on launching new medication to address neuropathic pain by investing in research and collaborating with other stakeholders in the supply chain. In addition, gaining approval from the FDA in a relatively short period of time continues to remain a major challenge for players operating in the current neuropathic pain therapeutics market.
Market players in different regions are opting for different growth strategies to gain an edge in the current market landscape. For instance, in April 2019, Daiichi Sankyo Company announced the launch of Tarlige ® Tablets for neuropathic treatment in Japan. The company revealed that the newly launched drug is likely to benefit patients who are suffering from peripheral neuropathic pain. While small-scale development of new drugs continues to gain momentum, several market players are increasingly focusing on collaborations to expand their existing product portfolio. For instance, in March 2019, Merck & Co., announced its plans of developing a new range of neuropathic pain treatments by leveraging technologies developed by FMedSci- a joint collaboration between two players. The company further revealed that the collaboration could potentially generate ~US$ 344 Mn in revenue for King’s College London. The collaboration is also aimed at addressing the unmet clinical requirements and developing new solutions to treat neuropathic pain. Such collaborations and joint ventures in the current market landscape are likely to positively impact the overall growth of the neuropathic pain therapeutics market.
As the healthcare sector around the world is predominantly engaged in containing the spread of the novel coronavirus, as a result, a number of surgical procedures, outpatient procedures, and drug development projects has either been delayed or completely canceled. Due to the growing number of hurdles put forward by the COVID-19 pandemic, the healthcare sector is finding new ways to address the requirements of patients suffering from chronic conditions, including neuropathic pain. Companies in the neuropathic pain therapeutics market are expected to focus on exploring different strategies to ensure the continuity in drug development particularly for opioids, biopsychosocial management, anti-inflammatory drugs, etc. The growing evidence stating that chronic pain patients are at a higher risk of getting infected by COVID-19 is another factor that is expected to provide a boost to drug development and research amid the ongoing COVID-19 pandemic.
Analysts’ Viewpoint
The global neuropathic pain therapeutics market is expected to grow at a moderate CAGR of ~5% during the forecast period. The market growth can be primarily linked to a host of factors, including growth in the elderly population worldwide, research and development activities, collaborations between pharmaceutical companies and research institutes, and launch of new drugs. Neuropathic pain therapeutics market players should largely focus on expanding their product portfolio and gain approval from the FDA for their products. Addressing the bottlenecks in the supply chain amid the ongoing COVID-19 pandemic should take center stage. In addition, market participants should also focus on curating effective business continuity strategies to gain an advantage in the current market landscape.
Neuropathic pain therapeutics market is expected to reach US$ 10.2 Bn by the end of 2030
Neuropathic pain therapeutics market is expected to grow at a moderate CAGR of ~5% from 2020 to 2030
Neuropathic pain therapeutics market is driven by rise in Geriatric Population and Prevalence of Diabetic Neuropathy
The anticonvulsants segment dominated the global neuropathic pain therapeutics market and the trend is likely to continue during the forecast period
Key players in the global neuropathic pain therapeutics market include Pfizer, Novartis AG, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Mallinckrodt Pharmaceuticals
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Neuropathic Pain Therapeutics Market
4. Market Overview
4.1. Introduction & Overview
4.2. Product Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, 2018–2030
5. Market Outlook
5.1. Pipeline Analysis
5.2. Treatment Guidelines
5.3. COVID-19 Pandemics Impact on Industry
6. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
6.2.1. Anticonvulsants
6.2.2. Antidepressants
6.2.2.1. Tricyclic Antidepressants
6.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
6.2.3. NSAIDs
6.2.4. Opioids
6.2.5. Steroids
6.2.6. Others
6.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class
7. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Indication, 2018–2030
7.2.1. Diabetic Neuropathy
7.2.2. Post-herpetic Neuralgia
7.2.3. Cancer-related Pain
7.2.4. Spinal Cord Injury
7.2.5. Others
7.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication
8. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Global Neuropathic Pain Therapeutics Market Value (US$) Forecast, by Route of Administration, 2018–2030
8.2.1. Oral
8.2.2. Topical
8.2.3. Others
8.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration
9. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel
10. Global Neuropathic Pain Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region
11. North America Neuropathic Pain Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
11.2.1. Anticonvulsants
11.2.2. Antidepressants
11.2.2.1. Tricyclic Antidepressants
11.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
11.2.3. NSAIDs
11.2.4. Opioids
11.2.5. Steroids
11.2.6. Others
11.3. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
11.3.1. Diabetic Neuropathy
11.3.2. Post-herpetic Neuralgia
11.3.3. Cancer-related Pain
11.3.4. Spinal Cord Injury
11.3.5. Others
11.4. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
11.4.1. Oral
11.4.2. Topical
11.4.3. Others
11.5. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
11.6.1. U.S.
11.6.2. Canada
11.7. North America Neuropathic Pain Therapeutics Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Neuropathic Pain Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
12.2.1. Anticonvulsants
12.2.2. Antidepressants
12.2.2.1. Tricyclic Antidepressants
12.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
12.2.3. NSAIDs
12.2.4. Opioids
12.2.5. Steroids
12.2.6. Others
12.3. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
12.3.1. Diabetic Neuropathy
12.3.2. Post-herpetic Neuralgia
12.3.3. Cancer-related Pain
12.3.4. Spinal Cord Injury
12.3.5. Others
12.4. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
12.4.1. Oral
12.4.2. Topical
12.4.3. Others
12.5. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Neuropathic Pain Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
13.2.1. Anticonvulsants
13.2.2. Antidepressants
13.2.2.1. Tricyclic Antidepressants
13.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
13.2.3. NSAIDs
13.2.4. Opioids
13.2.5. Steroids
13.2.6. Others
13.3. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
13.3.1. Diabetic Neuropathy
13.3.2. Post-herpetic Neuralgia
13.3.3. Cancer-related Pain
13.3.4. Spinal Cord Injury
13.3.5. Others
13.4. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
13.4.1. Oral
13.4.2. Topical
13.4.3. Others
13.5. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Neuropathic Pain Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
14.2.1. Anticonvulsants
14.2.2. Antidepressants
14.2.2.1. Tricyclic Antidepressants
14.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
14.2.3. NSAIDs
14.2.4. Opioids
14.2.5. Steroids
14.2.6. Others
14.3. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
14.3.1. Diabetic Neuropathy
14.3.2. Post-herpetic Neuralgia
14.3.3. Cancer-related Pain
14.3.4. Spinal Cord Injury
14.3.5. Others
14.4. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
14.4.1. Oral
14.4.2. Topical
14.4.3. Others
14.5. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Neuropathic Pain Therapeutics Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
15.2.1. Anticonvulsants
15.2.2. Antidepressants
15.2.2.1. Tricyclic Antidepressants
15.2.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
15.2.3. NSAIDs
15.2.4. Opioids
15.2.5. Steroids
15.2.6. Others
15.3. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
15.3.1. Diabetic Neuropathy
15.3.2. Post-herpetic Neuralgia
15.3.3. Cancer-related Pain
15.3.4. Spinal Cord Injury
15.3.5. Others
15.4. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
15.4.1. Oral
15.4.2. Topical
15.4.3. Others
15.5. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Competition Matrix
16.2. Market Share Analysis, by Company, 2019
16.3. Company Profiles
16.3.1. Novartis AG
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. GlaxoSmithKline plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. AstraZeneca
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Pfizer, Inc.
16.3.4.1. Company Overview (HQ, Business Segments)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Eli Lilly and Company
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Mallinckrodt Pharmaceuticals
16.3.6.1. Company Overview (HQ, Business Segments)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Johnson & Johnson
16.3.7.1. Company Overview (HQ, Business Segments)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Abbott
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Endo Pharmaceuticals, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Teva Pharmaceutical Industries Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Merck & Co., Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
List of Tables
Table 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 03: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 04: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 05: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 08: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 09: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 10: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 11: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 12: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 13: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 14: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 15: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 16: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 18: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 19: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 20: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 21: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 22: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 23: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 24: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 25: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 26: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 27: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 28: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 29: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 30: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 31: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 32: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Antidepressants, 2018–2030
Table 33: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 34: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 35: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 36: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
List of Figures
Figure 01: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2030
Figure 02: Global Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast, 2018–2030
Figure 03: Market Value Share, by Drug Class, 2019
Figure 04: Market Value Share, by Disease Type, 2019
Figure 05: Market Value Share, by Route of Administration, 2019
Figure 06: Market Value Share, by Distribution Channel, 2019
Figure 07: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 08: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticonvulsants, 2018–2020
Figure 09: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antidepressants, 2018–2020
Figure 10: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NSAIDs, 2018–2020
Figure 11: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Opioids, 2018–2020
Figure 12: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Steroids, 2018–2020
Figure 13: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020
Figure 14: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 15: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
Figure 16: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diabetic Neuropathy, 2018–2020
Figure 17: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Post-herpetic Neuralgia, 2018–2020
Figure 18: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer-related Pain, 2018–2020
Figure 19: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Spinal Cord Injury, 2018–2020
Figure 20: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020
Figure 21: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030
Figure 22: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 23: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2018–2020
Figure 24: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2018–2020
Figure 25: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2020
Figure 26: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 27: Global Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 28: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018–2030
Figure 29: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018–2030
Figure 30: Global Neuropathic Pain Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2018–2030
Figure 31: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 32: Global Neuropathic Pain Therapeutics Market, by Region, 2019 and 2030
Figure 33: Global Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Region, 2020–2030
Figure 34: North America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 35: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 36: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 37: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
Figure 38: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030
Figure 39: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 40: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 41: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 42: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 43: North America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country, 2019 and 2030
Figure 44: North America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country, 2020–2030
Figure 45: Europe Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 46: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 47: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 48: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
Figure 49: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030
Figure 50: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 51: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 52: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 53: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 54: Europe Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 55: Europe Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 56: Asia Pacific Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 57: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 58: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 59: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
Figure 60: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030
Figure 61: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 62: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 63: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 64: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 65: Asia Pacific Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 66: Asia Pacific Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 67: Latin America Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 68: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 69: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 70: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
Figure 71: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030
Figure 72: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 73: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 74: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 75: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 76: Latin America Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 77: Latin America Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 78: Middle East & Africa Neuropathic Pain Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 79: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Drug Class, 2019 and 2030
Figure 80: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Drug Class, 2020–2030
Figure 81: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Indication, 2019 and 2030
Figure 82: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Indication, 2020–2030
Figure 83: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 84: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 85: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 86: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 87: Middle East & Africa Neuropathic Pain Therapeutics Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 88: Middle East & Africa Neuropathic Pain Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Neuropathic Pain Therapeutics Market
